发明名称 USE OF COMPOUNDS HAVING CCR ANTAGONISM
摘要 It is intended to provide preventives/remedies for graft versus host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft versus host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having CCR (CC chemokine receptor) antagonism.
申请公布号 CA2483253(A1) 申请公布日期 2003.11.06
申请号 CA20032483253 申请日期 2003.04.23
申请人 TAKEDA PHARMACEUTICAL COMPANY LIMITED 发明人 TSUCHIMORI, NOBORU;SHIRAISHI, MITSURU;IIZAWA, YUJI;SUGIHARA, YOSHIHIRO
分类号 A61K31/351;A61K31/445;A61K31/4545;A61P1/00;A61P1/04;A61P1/14;A61P1/16;A61P1/18;A61P3/04;A61P3/10;A61P5/00;A61P7/00;A61P7/02;A61P7/10;A61P9/00;A61P9/04;A61P9/06;A61P9/10;A61P9/14;A61P11/00;A61P11/02;A61P11/06;A61P13/08;A61P13/10;A61P13/12;A61P15/00;A61P15/08;A61P17/00;A61P17/06;A61P19/00;A61P19/02;A61P19/10;A61P21/04;A61P25/00;A61P25/02;A61P25/04;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/22;A61P25/24;A61P25/28;A61P25/32;A61P27/06;A61P27/14;A61P27/16;A61P29/00;A61P31/06;A61P31/10;A61P31/12;A61P31/16;A61P31/18;A61P31/22;A61P35/00;A61P35/02;A61P35/04;A61P37/00;A61P37/06;A61P37/08;A61P39/00;A61P41/00;A61P43/00;(IPC1-7):A61K31/445;A61K31/454;A61K45/00;C07D211/14;C07D211/66;C07D211/96;C07D309/14 主分类号 A61K31/351
代理机构 代理人
主权项
地址